Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press113910.17650/1994-4098-2023-19-3-63-76MAMMOLOGY. REVIEWSМАММОЛОГИЯ. ОБЗОРНЫЕ СТАТЬИTrastuzumab deruxtecan in the treatment of patients with advanced breast cancer with HER2-low expression: Recent studies reviewТрастузумаб дерукстекан в лечении больных распространенным раком молочной железы с HER2-low экспрессией: по следам исследований последних летhttps://orcid.org/0000-0002-1124-6802KolyadinaI. V.КолядинаИ. В.
Russian Federation

Irina Vladimirovna Kolyadina

2/1 Barrikadnaya St., Moscow 125993; 4 Akademika Oparina St., Moscow 117198

Ирина Владимировна Колядина

125993 Москва, ул. Баррикадная, 2/1, стр. 1; 117997 Москва, ул. Академика Опарина, 4

irinakolyadina@yandex.comRussian Medical Academy of Postgraduate Education, Ministry of Health of RussiaФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииV.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. акад. В.И. Кулакова» Минздрава России2710202319363762710202327102023https://ojrs.abvpress.ru/ojrs/article/view/1139

The review gives the definition of HER2-low status, shows its clinical and biological role in patients with advanced breast cancer. A unique mechanism of action of trastuzumab deruxtecan and potential for its use in advanced breast cancer with HER2-low expression are described. The key results of the open multicenter phase III DESTINY-Breast04 (DB-04) trial including safety data are presented. Results on the effectiveness of the drug in patients with markers of hormone resistance first presented in 2023 and the place of trastuzumab deruxtecan in the updated ESMO 2023 algorithm of hormone-positive breast cancer treatment are considered.

В представленном обзоре дано определение HER2-low статуса, показана его клиническая и биологическая роль у больных распространенным раком молочной железы. Раскрыт уникальный механизм действия трастузумаба дерукстекана и потенциал применения препарата при распространенном раке молочной железы с HER2-low экспрессией. Представлены ключевые результаты открытого многоцентрового исследования III фазы DESTINY-Breast04 (DB-04), в том числе данные по безопасности терапии. Отражены впервые представленные в 2023 г. результаты эффективности препарата у больных с наличием маркеров гормонорезистентности, а также место трастузумаба дерукстекана в обновленном алгоритме ESMO 2023 по лечению распространенного гормонозависимого рака молочной железы.

breast cancer with HER2-low expressiontrastuzumab deruxtecanmulticenter DESTINY-Breast04 trialhormone resistanceESR1 mutationPIК3CA mutationER-low expressiontreatment algorithm for advanced breast cancerрак молочной железы с HER2-low экспрессиейтрастузумаб дерукстеканмногоцентровое исследование DESTINY-Breast04гормонорезистентностьмутация ESR1мутация PIK3CAER-low экспрессияалгоритм лечения распространенного рака молочной железыThe work was performed without external fundingРабота выполнена без спонсорской поддержкиTyulyandin S.A., Artamonova E.V., Zhukova L.G. et al. Practical recommendations for drug treatment of breast cancer. Malignant tumors: Practical recommendations RUSSCO #3s2, 2022 (vol. 12). Pp. 155–197. (In Russ.)Тюляндин С.А., Артамонова Е.В., Жукова Л.Г. и др. Практические рекомендации по лекарственному лечению рака молочной железы. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2022 (том 12). С. 155–197.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Version 4.2023.Gennari A., André F., Barrios C.H. et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 2021;32(12):1475–95. DOI: 10.1016/j.annonc.2021.09.019Wolff A.C., Hale Hammond M.E., Allison K.H. et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol 2018;36:2105–22. DOI: 10.1200/JCO.2018.77.8738Schettini F., Chic N., Brasó-Maristany F. et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer 2021;7(1):1. DOI: 10.1038/s41523-020-00208-2Tarantino P., Hamilton E., Tolaney S.M. et al. HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol 2020;38(17):1951–62. DOI: 10.1200/JCO.19.02488Modi S., Park H., Murthy R.K. et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HHER2-lowexpressing advanced breast cancer: Results from a phase Ib study. J Clin Oncol 2020;38(17):1887–96. DOI: 10.1200/JCO.19.02318Lin M., Luo T., Zhang H. et al. HER2-low status discordance between primary and recurrent/metastatic breast cancer in a largescale cohort. J Clin Oncol 2023;41(Suppl 16):abstr. 1021. DOI: 10.1200/JCO.2023.41.16_suppl.1021Bar Y., Dedeoglu A.S., Fell G.G. et al. Dynamic HER2-low status among patients with triple negative breast cancer (TNBC): The impact of repeat biopsies. J Clin Oncol 2023;41(Suppl 16): abstr. 1005. DOI: 10.1200/JCO.2023.41.16_suppl.1005Nakada T., Sugihara K., Jikoh T. et al. The latest research and development into the antibody-drug conjugate, [fam–] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. Chem Pharm Bull (Tokyo) 2019;67:173–85. DOI: 10.1248/cpb.c18-00744Ogitani Y., Aida T., Hagihara K. et al. DS-8201a, a novel HER2targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM. Clin Cancer Res 2016;22:5097–108. DOI: 10.1158/1078-0432.CCR-15-2822Modi S., Jacot W., Yamashita T. et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 2022;387(1):9–20. DOI: 10.1056/NEJMoa2203690Modi S. Trastuzumab deruxtecan in previously treated HER2positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study. Future Oncol 2021;17(26):3415–23. DOI: 10.2217/fon-2021-0427Cortés J., Kim S., Chung W. et al. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study. Ann Oncol 2021;32(Suppl 5): S1283–S1346. DOI: 10.1016/annonc/annonc741Rugo H.S. Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): A detailed safety analysis of the randomized, phase 3 DESTINY-Breast04 trial. ESMO BC 2023. Oral presentation #1850.Modi S., Niikura N., Yamashita T. et al. Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR+) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04. ASCO 2023. Poster #1020.Cameron D.A. DESTINY-Breast04 subgroup analyses of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with human epidermal growth factor 2 (HER2)-low, estrogen-receptor (ER) expression immunohistochemistry (IHC) 0–10 % metastatic breast cancer (mBC). ESMO BC 2023. Oral presentation #192MO.Im S.-A., Gennari A., Park Y.H. et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer. ESMO Open 2023;8(3):101541. DOI: 10.1016/j.esmoop.2023.101541